Beam Therapeutics (NASDAQ: BEAM), a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated data from its BEACON Phase 1/2 trial of BEAM-101 at the European Hematology Association 2025 Congress, June 12-15 in Milan. BEAM-101 is an investigational, one-time ex vivo cell therapy targeting severe vaso-occlusive crises in sickle cell disease (SCD). The new data, covering safety and efficacy outcomes in 17 patients, will be highlighted during multiple poster sessions on June 13, underscoring BEAM-101’s potential to provide a durable treatment by addressing the root cause of SCD. Additional presentations will explore biomarkers, manufacturing advances, and red blood cell health post-treatment. Beam will also host a webcast on June 13 at 4:00 p.m. ET to review EHA highlights.
To view the full press release, visit https://ibn.fm/Neujg
About Beam Therapeutics
Beam Therapeutics (NASDAQ: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
For more information, visit the company’s website at: https://beamtx.com/
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
